The average of price targets set by Wall Street analysts indicates a potential upside of 75.6% in Va

Cantor Fitzgerald analyst Carter Gould reiterates Vaxcyte (NASDAQ:PCVX) with a Overweight and ann

Stephen King slammed Trump’s incoming press secretary over her vaccine conspiracy theories and contr

What happened Vaxcyte, Inc. (NASDAQ: PCVX) closed a financing on October 9, 2026, and sold $575 mill

A new NIH-backed initiative to speed up personalized cancer vaccine development sent stocks like MRN

Vaxcyte, Inc. (NASDAQ: PCVX - Get Free Report) EVP Jim Wassil sold 18,000 shares of the company's st

SAN CARLOS, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage

Vaxcyte remains a 'Strong Buy' after robust phase 3 OPUS-1 results for VAX-31, demonstrating non-inf

U.S. stocks rose Tuesday: Dow +350 points, S&P 500 +0.86%. Lamb Weston jumped 12% on strong resu

Vaxcyte, Inc. (NASDAQ: PCVX - Get Free Report) shares saw unusually-strong trading volume on Tuesday

U.S. stock futures were higher on Tuesday, as the Dow Jones, S&P 500 and Nasdaq 100 indices rose

Vaxcyte (NASDAQ: PCVX) said its investigational 31-valent pneumococcal conjugate vaccine, VAX-31, me

U.S. stock futures rose, while Goosehead fell after a downgrade; NFT, Armada and other stocks also s

Option Care Health jumped 23.8% on reports McKesson and CD&R may acquire it; Freight Technologie

Vaccine stocks are trending on Tuesday. Shares of Moderna Inc. (NASDAQ:MRNA), Vaxcyte Inc. (NASDA

Vaxcyte NASDAQ: PCVX said its investigational 31-valent pneumococcal conjugate vaccine, VAX-31, met

SAN CARLOS, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage

Vaxcyte, Inc. (PCVX) Discusses Top Line Results From OPUS-1 Phase 3 Trial of VAX-31 Pneumococcal Vac

Needham analyst Joseph Stringer maintains Vaxcyte (NASDAQ:PCVX) with a Buy and raises the price t

Gainers HeartBeam (NASDAQ:BEAT) stock moved upwards by 70.5% to $0.74 during Monday's regular s

U.S. stocks rose Monday: Dow +0.2%, S&P 500 +0.62%, Nasdaq +0.84%. Materials led; ISM services P

Vaxcyte (NASDAQ:PCVX) shares surged 57% in morning trading on Monday after the biotechnology company

Vaxcyte, Inc. (NASDAQ: PCVX - Get Free Report) saw unusually large options trading activity on Monda

Vaxcyte is poised to capture significant share of a $3 billion to $6 billion market following the la

Shares of Vaxcyte, Inc. (NASDAQ: PCVX - Get Free Report) reached a new 52-week high on Monday. The c

U.S. stocks mixed as Dow falls 250+ points; RXO surges 23% on $5.8B C.H. Robinson deal, while Vaxcyt

Vaxcyte Inc. (NASDAQ:PCVX) stock is surging on Monday on positive topline results from its pivotal P

Vaxcyte announced positive Phase 3 OPUS-1 trial results for its VAX-31 vaccine candidate, setting th

Guggenheim analyst Seamus Fernandez maintains Vaxcyte (NASDAQ:PCVX) with a Buy and raises the pri

Gainers Apimeds Pharmaceuticals (AMEX:APUS) stock moved upwards by 76.7% to $5.69 during Monday&#39

VAX-31 Met All Prespecified Primary Endpoints Across Age Groups Studied Compared to Prevnar 20 (PCV2

VAX-31 Met All Prespecified Primary Endpoints Across Age Groups Studied Compared to Prevnar 20® (PCV

SAN CARLOS, Calif., Oct. 04, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage

Analysts raised targets for Vertex and Okta, while cutting targets for McDonald’s, AutoZone, Vaxcyte

B of A Securities analyst Jason Gerberry maintains Vaxcyte (NASDAQ:PCVX) with a Buy and lowers th

KOD, CLDX, RAPP and PCVX face key clinical readouts this fall that could influence their drug and va

California State Teachers Retirement System boosted its position in Vaxcyte, Inc. (NASDAQ: PCVX) by

Vaxcyte, Inc. (NASDAQ: PCVX - Get Free Report) was the recipient of some unusual options trading on

Value investor Seth Klarman reveals his latest stock picks in a second quarter filing for hedge fund

Vaxcyte (NASDAQ:PCVX) reported quarterly losses of $(1.97) per share which beat the analyst consensu

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

The health care sector's most oversold stocks are a buying opportunity due to undervalued compan

Vaxcyte (NASDAQ:PCVX) reported quarterly losses of $(2.30) per share which missed the analyst consen

Vaxcyte's next-generation 31-valent pneumococcal conjugate vaccine (PCV) candidate, for the prev

Based on the Strength of Unprecedented Results from the Positive Phase 1/2 Study in Adults Aged 50 a

BTIG analyst Thomas Shrader maintains Vaxcyte (NASDAQ:PCVX) with a Buy and raises the price targe

Vaxcyte (NASDAQ:PCVX) reported quarterly losses of $(1.80) per share which missed the analyst consen